Calcineurin is a calcium (Ca 2þ )/calmodulin-regulated protein phosphatase that mediates Ca 2þ -dependent signal transduction. Here, we report six heterozygous mutations in a gene encoding the alpha isoform of the calcineurin catalytic subunit (PPP3CA mutations, two missense mutations were found in the auto-inhibitory (AI) domain. One additional frameshift insertion that caused premature termination was also identified. Detailed clinical evaluation of the six individuals revealed clinically unexpected consequences of the PPP3CA mutations. First, the catalytic domain mutations and frameshift mutation were consistently found in patients with nonsyndromic early onset epileptic encephalopathy. In contrast, the AI domain mutations were associated with multiple congenital abnormalities including craniofacial dysmorphism, arthrogryposis and short stature. In addition, one individual showed severe skeletal developmental defects, namely, severe craniosynostosis and gracile bones (severe bone slenderness and perinatal fractures). Using a yeast model system, we showed that the catalytic and AI domain mutations visibly result in decreased and increased calcineurin signaling, respectively. These findings indicate that different functional effects of PPP3CA mutations are associated with two distinct disorders and suggest that functional approaches using a simple cellular system provide a tool for resolving complex genotype-phenotype correlations.
Introduction
Calcineurin is a heterodimer composed of two subunits: catalytic A (CnA) and regulatory B (CnB) subunits. For full activation of calcineurin, a third component, calmodulin (CaM), binds to CnA (1) . This protein complex functions as a serine/threoninespecific protein phosphatase that regulates the phosphorylation status of a large number of downstream targets, including transcription factors, ion channels and cytoskeletal proteins (2) . Both CnB and CaM are calcium (Ca 2þ )-binding proteins that activate CnA activity in response to increased intracellular Ca 2þ . The C-terminal region of CnA contains an auto-inhibitory (AI) domain (3) . In an inactive state, the AI domain is thought to interact with the catalytic active site of CnA and inhibit enzyme activity. Binding of Ca 2þ to the regulatory proteins, CnB and
CaM, results in conformational change of CnA that displaces the AI domain from the catalytic active site and leads to full activation of CnA (2, 4) . Upon activation, CnA dephosphorylates several substrates, including a well-known transcription factor family, nuclear factor of activated T cells (NFAT). Calcineurin can regulate gene expression through NFAT, which normally localizes to the cytoplasm but translocates to the nucleus when dephosphorylated. After its nuclear translocation, NFAT binds to gene promoters and regulates the expression of downstream target genes. As such, calcineurin responds to increased intracellular Ca 2þ levels to translate this signal for transcriptional regulation via NFAT. Although this pathway is suggested to play a role in the development and/or function of many organ systems, including the immune, nervous, cardiovascular, musculoskeletal and urinary systems (5) , evidence of its mutational consequences in humans is limited. Very recently, a large-scale exome analysis focusing on de novo mutations highlighted protein phosphatase 3 catalytic subunit alpha (PPP3CA) as a new candidate for neurodevelopmental disorder with epilepsy (6) . Although de novo mutations of PPP3CA were statistically enriched in a large combined cohort, pathogenicity of its mutations and possible genotypephenotype correlations need to be resolved. Genetic data combined with effective functional studies may provide new insight into the underlying mechanisms and genotype-phenotype correlations.
Here, our group identified PPP3CA mutations in six families (five novel and one reported) and extensively assessed their effects on the calcineurin signaling pathway using the fission yeast, Schizosaccharomyces pombe, as a model system. Notably, two functionally distinct types of mutations were experimentally demonstrated: loss-of-function and constitutively activating mutations at catalytic and AI domains, respectively. Surprisingly, these two mutational types led to clinically distinct phenotypes. Detailed mutational and clinical features are described here.
Results

Identification of de novo PPP3CA mutations
We initially performed trio-based whole-exome sequencing (WES) for Family 1. After filtering, two heterozygous de novo variants were identified: c.702C>G (p.Asp234Glu) in PPP3CA and c.412G>A (p.Glu138Lys) in KDM1A (encodes lysine-specific demethylase 1A). These two variants were not present in dbSNP Build 150, Exome Aggregation Consortium (ExAC) or our inhouse Japanese exome controls (n ¼ 575 individuals). PPP3CA is highly expressed in mammalian brain tissue. The c.702C>G variant was predicted to be pathogenic by four bioinformatic tools: SIFT, Polyphen2, CADD and MutationTaster (Supplementary Material, Table S1 ). KDM1A is expressed in various tissues including the brain, and c.412G>A was deemed pathogenic based on at least two bioinformatic tools (Polyphen2 and MutationTaster). These two genes are potentially causal in the family. Next, we searched for PPP3CA or KDM1A mutations in our WES datasets of cases with epilepsy (n ¼ 1456) to identify unrelated individuals with potential variants in these genes. We identified four additional rare variants in PPP3CA but none in KDM1A. Thus, altogether we identified five rare variants in PPP3CA (four missense and one frameshift). Four of them occurred de novo and were confirmed by Sanger sequencing: c.702C>G (p.Asp234Glu), c.275A>G (p.His92Arg), c.1290dupC (p.Met431Hisfs*20) and c.1417G>A (p.Ala473Thr) in Families 1, 3, 4 and 6, respectively (Fig. 1A) . In Family 2, paternal DNA was unavailable and maternal inheritance of c.449A>T (p.Asn150Ile) was ruled out (Fig. 1A) . Constraint metrics in ExAC showed that PPP3CA is under constraint for missense (Z score ¼ 3.89) and loss-of-function [probability of being loss-of-function intolerant (pLI) ¼ 1.00] variants. This evidence strongly supports the pathogenicity of PPP3CA variants. In functional studies of these variants, Myers et al. reported significant enrichment of de novo PPP3CA variants in neurodevelopmental disorders by exome and targeted sequencing analysis of 4760 trios (6) . Collectively, these findings suggest that de novo heterozygous variants in PPP3CA can cause epilepsy.
PPP3CA functional domains, mutations and clinical features
PPP3CA contains one catalytic and three regulatory domains, including calcineurin B binding (CnBB), calmodulin binding (CaMB) and AI domains (Fig. 1B) . Of three missense variants at the catalytic domain, p.His92Arg and p.Asn150Ile (but not p.Asp234Glu) are present in metal binding sites of the phosphoesterase motif (1) (Fig. 1B) . All three catalytic domain variants altered evolutionarily conserved amino acids from human to yeast, and were predicted to be pathogenic by SIFT, Polyphen2, CADD and MutationTaster (Supplementary Material, Table S1 ). Individuals with catalytic domain mutations showed similar clinical manifestations. They had non-syndromic epileptic encephalopathy with spasms and hypsarrhythmia as determined by electroencephalography (EEG), leading to a clinical diagnosis of West syndrome (Table 1 , Supplementary Material, Figs S1 and S2). One additional frameshift variant, c.1290dupC (p.Met431Hisfs*20), was also identified in an individual with nonsyndromic epileptic encephalopathy (Table 1) . Her initial diagnosis was also West syndrome. These observations suggest that these variants have a similar impact on PPP3CA function and cause early onset epileptic encephalopathy.
We also identified a de novo missense variant (c.1417G>A, p.Ala473Thr) at the AI domain (aa 465-487 based on UniProtKB: Q08209) in a boy who showed not only developmental delay with seizure but also dysmorphic features, including trigonocephaly, Fig. S3 ). Unlike patient 6, patient 5 showed severe slenderness of the ribs and tubular bones, and perinatal fractures (gracile bones) ( Fig. 2A-F) . Moreover, craniosynostosis was more overt in patient 5 than in patient 6. In contrast, patient 6 exhibited developmental delay with seizures. The phenotype of patient 5 was reminiscent of osteocraniostenosis, an autosomal dominant disorder arising from mutations in family with sequence similarity 111 member A (FAM111A) (7). However, FAM111A was normal in our exome data (mean coverage of FAM111A coding sequence was 117.18Â, with at least 96% of target bases sequenced by ! 20 reads). Based on patients 5 and 6, we re-evaluated extra-neurological findings in individuals with catalytic domain mutations but did not find even subtle dysmorphic signs in any individuals except for microcephaly in patient 2. Thus, developmental delay and ID/MCA are likely to be associated with mutations at the AI domain. These clinical manifestations are summarized in Table 1 , with case reports presented in the Materials and Methods section. In summary, we suggest that PPP3CA variants in different functional domains (catalytic versus AI domains) cause two distinct (allelic) disorders.
Structural impact of five missense variants
To evaluate the impact of the identified mutations on human calcineurin structure, we mapped mutation sites onto the crystal structure of human calcineurin heterodimer (PDB code: 1AUI) (8) . In this structure, the AI domain interacts with the catalytic center (Fig. 1C ). Residues at the mutation sites, His92 and Asn150, correspond to the catalytic ions, iron and zinc, respectively. Thus, p.His92Arg and p.Asn150Ile mutations may impair correct folding and enzymatic activity. The Asp234 side chain forms hydrogen bonds with Arg254, which is highly conserved among species and reportedly positioned to bind phosphate oxygen in the substrate (8) (Fig. 1D ). Thus, catalytic activity is predicted to be impaired when Asp234 is replaced with a glutamate residue, which has a slightly longer side chain than that of an aspartate residue. Phe470 and Ala473 in the a-helix of the AI domain were located at the surface involved in the interaction between the AI domain and the catalytic domain with the hydrophobic core (Fig. 1E) . Consequently, p.Phe470Leu and p.Ala473Thr mutations are likely to destabilize the interaction between AI and catalytic domains, leading to impaired autoinhibition of catalytic activity by the AI domain. We also calculated the change in free energy of each mutation using FoldX software 2 (9) (Fig. 1F ). All tested mutations showed at least 2 kcal/mol increases in free energy, potentially leading to instability of protein folding and supporting our above discussion.
Functional relevance of PPP3CA mutations
In silico modeling suggested that both catalytic and AI domain mutations affected the domain structure or overall folding of PPP3CA.
To study the functional effects of these variants, we used the fission yeast S. pombe as a model system for examining calcineurin signaling. The ppb1 gene encodes a calcineurin catalytic subunit (CnA) in S. pombe (10) . The amino acid sequence of ppb1 was 63% identical to that of human PPP3CA with a highly conserved primary domain structure (Supplementary Material, Fig. S4 ). Ppb1 is not an essential gene but is required for viability in specific growth conditions such as those with high extracellular Ca 2þ . As previously shown (11), the ppb1 deletion strain (ppb1D) grows well under standard conditions but has a growth defect in high-Ca 2þ conditions (Fig. 3A) . Full-length ppb1 cDNA was cloned into the S. pombe expression vector, pREP1, and transformed into ppb1D. Ten-fold serial dilution of a yeast strain ectopically expressing wild-type ppb1 was spotted and grown at 32 C. As expected, the Ca 2þ -hypersensitive phenotype was fully rescued by ectopic expression of wildtype ppb1 but not empty vector (Fig. 3A) . Accordingly, this assay enabled us to evaluate the in vivo function of mutant proteins. In mammalian cells, response to Ca 2þ influx triggered by synaptic neurotransmission is crucial for proper neuronal activity (12) . -induced transcriptional regulation is mediated by calcineurin. To distinguish the functional impact of catalytic and AI domain mutations at the transcriptional level, we monitored ncs1 and pmc1 expression by real-time PCR. When wild-type ppb1 was overexpressed, both pmc1 and ncs1 were upregulated after Ca 2þ stimulation,
showing activation of the calcineurin signal (Fig. 3B) . Consistent with the lack of growth rescue by dilution assay (Fig. 3A) , transcriptional upregulation of ncs1 and pmc1 was not observed with the three catalytic domain mutants (Fig. 3B) . Interestingly, derepression of calcineurin signaling was consistently observed with the two AI domain mutants, as indicated by increased expression of both pmc1 and ncs1 without Ca 2þ stress (Fig. 3C ). Similar observations were found with other downstream target genes of calcineurin, such as SPBPB21E7.04c and SPCC737.04 (14) , suggesting that a pleiotropic (or even generalized) phenotype is potentially produced by AI domain mutations ( Fig. 3D and E).
Enzymatic effects of catalytic and AI domain mutations
The basic mechanism of the calcineurin-NFAT signal is conserved in the yeast model system. Transcriptional upregulation of pmc1 and ncs1 is mediated by a calcineurin-activated transcription factor, Prz1. Prz1 is dephosphorylated by calcineurin and translocates from the cytoplasm to the nucleus for transcriptional regulation (11) . Transcriptional dysregulation ( Fig. 3B-E ) of catalytic and AI domain mutants suggests that the phosphatase activity of calcineurin might be affected by missense mutations. To study changes in calcineurin phosphatase function, we investigated the activation status of Prz1. First, we generated a yeast strain endogenously expressing C-terminal HA-tagged Ppb1 (Ppb1-HA WT ). This strain was not sensitive to Ca 2þ , indicating that the fusion protein is functional (Fig. 4A) ). Western blotting showed comparable protein levels between Ppb1 mutants and the wild type, suggesting that catalytic and AI domain mutations do not affect protein stability (Fig. 4B) . Consistent with a loss-of-function effect in rescue experiments (Fig. 3A) , Ppb1-HA catalytic domain mutants showed hypersensitivity to high Ca 2þ levels, similar to ppb1D. The same levels of Ca 2þ sensitivity were obtained by pharmacological inhibition of calcineurin activity using FK506 (FK506-treated wildtype cells versus catalytic domain mutants). These observations suggest that catalytic domain mutants are functionally null with respect to enzymatic action (Fig. 4A) .
To directly confirm this possibility, we studied Prz1 modification. The prz1 gene was chromosomally tagged with GFP at an endogenous locus on the wild-type and ppb1 mutant backgrounds. The phosphorylation status of Prz1 could be identified by a mobility shift on SDS-PAGE gels followed by western blotting. Consistent with previous reports (11), Prz1 showed slower and faster migration in the absence and presence of Ca 2þ , respectively (Fig. 4C) . Ca 2þ -induced mobility shift was inhibited by FK506 treatment, suggesting that this change is indeed related to calcineurin activity (Fig. 4C) . We then tested whether catalytic domain mutations were associated with defective Prz1 modification. Unlike wild-type cells, Prz1 did not show a mobility shift with catalytic domain mutants after Ca 2þ stress, indicating that ppb1 is enzymatically inactive (Fig. 4D ). This conclusion was supported by live-cell imaging showing that Prz1 does not translocate to the nucleus in high-Ca 2þ conditions (Fig. 4E) . In contrast to catalytic domain mutants, we found that Prz1 of AI domain mutants migrated faster than either wildtype or catalytic domain mutants in the absence of Ca 2þ stress (Fig. 4D) . Consistent with this, the proportion of cells showing nuclear translocation increased in AI domain mutants without Ca 2þ stimulation (Fig. 4E) (6) . Although the third mutation, p.Asp234Glu, is not located at a metal binding site, yeast studies indicated that this was also a loss-of-function mutation, similar to p.His92Arg and p.Asn150Ile. Therefore, we suggest that loss-of-function (or null) mutations are associated with West syndrome, regardless of their position within the functional domain. Nonetheless, mutations in the catalytic domain are not always functionally null. Two reported pathogenic mutations (6), p.His281Gln and p.Glu282Lys, are positioned adjacent to each other (Supplementary Material, Fig. S7A ) and predicted to be pathogenic by three (SIFT, Polyphen2 and MutationTaster) and four (SIFT, Polyphen2, CADD and MutationTaster) bioinformatic tools, respectively (Supplementary Material, (6) . Such functional differences between mutations might be associated with phenotypic differences in patients with catalytic domain mutations. AI domain mutations were associated with multiple congenital abnormalities. Two patients with AI domain mutations shared certain clinical features, including developmental delay, craniosynostosis, cleft palate, micrognathia, arthrogryposis and short stature. However, patient 5 distinctively showed gracile bones, as well as markedly severe craniosynostosis. This phenotype is reminiscent of osteocraniostenosis arising from heterozygous FAM111A mutations. Nevertheless, patient 5 did not have a FAM111A mutation nor other hallmark of osteocraniostenosis (such as ocular malformations, splenic hypoplasia and hypocalcemia). In contrast, patient 5 exhibited arthrogryposis (congenital multiple joint contractures), which is not seen in osteocraniostenosis (7) . Severe fetal hypokinesia may create slender bones with or without intrauterine fractures (16) . Therefore, this patient's gracile bones may have been a secondary consequence of the fetal hypokinesia sequence, and not an essential syndromic component. Alternatively, calcineurin signaling might have in vivo effects on skeletal bone development in humans. In fact, it was reported that calcineurin/NFAT signaling is probably involved in bone remodeling in mice (17, 18) . Such a bone phenotype might be influenced by environmental and/or genetic modifiers. More studies are needed to establish the clinical features of patients with AI domain mutations.
In this study, we observed tissue-specific alternative splicing of PPP3CA, which may affect mutational consequences. In general, NMD is inefficient when PTC occurs at the last exon or last <50 bp of the penultimate exon (19) . In patient 4, PTC occurs in the penultimate exon (exon 13) of transcript variant 1. Meyers et al. reported PPP3CA non-sense mutation (c.1333C>T, p.Gln445*) at exon 12 of transcript variant 1, which is more upstream than the PTC position of our patient 4's mutation (p.Met431Hisfs*20). However, the PTC positions of both mutations were supposed to be located within the <50 bp region from the last exon-exon junction as exon 13 is too short (only 30 bp) and may escape from NMD in brain-specific transcript variant 1. If NMD is inefficient, as with variant 2 in LCL, a dominant-negative and/or gain-of-function effect might be a possible mechanism. However, we cannot fully rule out the possibility that tissue-specific NMD may degrade mutant transcripts in the brain and lead to a haploinsufficient phenotype, similar to catalytic domain mutations. In fact, many exceptions have been reported that do not follow the general rules for NMD efficiency (20) (21) (22) . The precise mechanism of these two mutations has yet to be proved.
Numerous genes with different functions cause West syndrome. It remains possible that certain treatments will be more effective in specific subtypes, for example, vigabatrin for tuberous sclerosis complex patients (23) . In our yeast study, CnA catalytic domain but not AI domain mutants were hypersensitive to an anti-epileptic drug, valproic acid (Supplementary Material, Fig. S6 ). As such, PPP3CA-epileptic encephalopathy might exhibit a unique pharmacological cellular response. The therapeutic response is definitely more complicated and it is not easy to predict drug effectiveness based on the data from experiments using a unicellular organism. Indeed, two patients partially responded to valproic acid (patients 1 and 4), while the others did not (patients 2 and 3). However, future efforts based on pathophysiological mechanisms may lead to better therapeutic strategies. Molecules downstream of calcineurin signaling might be potentially pharmacological targets (24) .
In summary, we have provided evidence for the involvement of calcineurin in the pathogenesis of different human phenotypes. Loss-of-function and gain-of-function mutations of PPP3CA lead to early onset epileptic encephalopathy and multiple congenital abnormalities, respectively. These two allelic conditions may be derived from the differing nature of PPP3CA mutations. This study clearly indicates that functional evaluation of mutations is important for understanding new pathogenic mechanisms and clear genotype-phenotype correlations.
Materials and Methods
Case reports
Patient 1 was the first child of unrelated healthy parents. He was born at 40 weeks of gestation after an uneventful pregnancy. Phototherapy was used for 3 days to treat neonatal jaundice. At the age of 6 months, he was referred to our hospital as no head control had been acquired. Routine blood chemistry was normal except for mild elevation of liver transaminase [aspartate transaminase (AST)/alanine transaminase (ALT), 84/50 IU/L]. Brain CT was normal. Chromosomal karyotype was 46, XY. He showed head nodding or spasm-like movements at 7 months, and their frequency gradually increased and they appeared in clusters. At 10 months of age, he showed profound developmental delay. His developmental quotient (DQ) was 14 (based on the Japanese Enjoji scale for infantile development) and interictal EEG showed hypsarrhythmia (Supplementary Material, Fig. S1A ), leading to a diagnosis of West syndrome. Myoclonic seizures were observed on ictal video EEG as well as epileptic spasms. Brain MRI showed frontal-dominant mild brain atrophy (Supplementary Material, Fig. S2A and B) . Other laboratory examinations were all normal, including blood chemistry, lactate and pyruvate in cerebrospinal fluid, plasma amino acids, serum acylcarnitine, urine organic acids, visual evoked potential and auditory brainstem response. His seizures on EEG transiently disappeared after 25 days of adrenocorticotropic hormone (ACTH) injection, but high-amplitude epileptic discharges remained at bilateral occipital lobes on EEG. These partially responded to valproic acid, but the adverse effect of thrombocytopenia prevented an increase in dose. At 14 months of age, the epileptic spasms in clusters relapsed, and were refractory to multiple anti-epileptic drugs, such as pyridoxal phosphate, zonisamide, clobazam, topiramate, lamotrigine and a modified Atkins/ketogenic diet. At 25 months of age, he still had epileptic spasms in clusters twice a day. His height was 86.0 cm (À0.1 SD), weight 9.7 kg (À1.8 SD) and head circumference 48.0 cm (À0.2 SD). He showed profound developmental delay (DQ 7 in the Japanese Enjoji scale), hypotonic quadriplegia, unstable head control, no eye contact and no meaningful words. His EEG showed frontal-dominant multifocal epileptic discharges with increased frequency and generalization during the sleep state (Supplementary Material, Fig. S1B ).
Patient 2 was born by spontaneous delivery at 38 weeks of gestation after an uneventful pregnancy. She obtained head control at 4 months of age, but acquired social smiling at 5 months of age, indicating developmental delay. At 8 months of age, she developed daily epileptic spasms in clusters with hypsarrhythmia on EEG, leading to a diagnosis of West syndrome. ACTH injection therapy was temporarily effective for her seizures with a partially improved EEG; however, multiple types of generalized seizures (including tonic seizures, atonic seizures and atypical absence seizures) appeared daily. These were refractory to multiple anti-epileptic drugs such as pyridoxal phosphate, valproic acid, clonazepam, nitrazepam, levetiracetam and acetazolamide. Some anti-epileptic drugs, such as clobazam, phenytoin, zonisamide, topiramate, lamotrigine and potassium bromide, were partially effective against the seizures. Her EEG frequently showed diffuse spike-and-slow waves and polyspike-and-slow waves (Supplementary Material, Fig.  S1C ), which were compatible with a diagnosis of LennoxGastaut syndrome. She had characteristic features of Rett syndrome such as autistic behavior, hand stereotypies (e.g. hand wringing), and tooth grinding. At 19 years of age, her height was 150.4 cm (À1.5 SD), weight 38.5 kg (À1.9 SD) and head circumference 52.4 cm (À2.3 SD). She showed profound ID with no meaningful words. She could roll over by herself but could not sit alone. Head CT at 7 months of age showed no calcification. MRI at 2 years of age showed mild brain atrophy, but this was normal by 8 years of age (Supplementary Material, Fig. S2C and D) . EEG at 19 years of age showed frequent diffuse polyspike-andslow waves during the sleep state (Supplementary Material, Fig.  S1D ).
Patient 3 was the third child born to unrelated healthy parents. She was born spontaneously at 38 weeks of gestation with no asphyxia. She was referred to our hospital at 16 months because of developmental delay, namely, eye pursuit of an object at 3 months of age, social smiling at 4 months, head control at 5 months and sitting without support at 14 months. She had monthly epileptic spasms at 22 months of age, and the frequency of her seizures increased on a weekly basis at 2 years of age. Video EEG demonstrated epileptic spasms in clusters, with polyspike-and-slow waves at the occipital area and right dominancy during the sleep state (Supplementary Material, Fig. S1E ). Her seizures were refractory to ACTH injection and multiple anti-epileptic drugs such as valproic acid, clobazam and zonisamide. Lamotrigine partially reduced the frequency of her seizures. She showed neither dysmorphisms nor involuntary movements. Her DQ was 27 (Kyoto Scale of Psychological Development) at 2 years and 8 months of age. At 3 years and 10 months, her height was 91 cm (À2.0 SD) and body weight 14 kg (À0.5 SD). She could walk with support but was unable to speak meaningful words. Her brain MRI was normal at 17 months and head CT showed no calcification. Mild dilatation of sulci and lateral ventricles was detected immediately after ACTH injection therapy at 2 years and 8 months but had normalized by 4 years of age (Supplementary Material, Fig. S2E and F) . EEG findings changed during her development: no paroxysmal discharge at 2 years and 5 months, bilateral frontopolar sharp waves at 2 years and 7 months (Supplementary Material, Fig. S1F ), and focal polyspike-and-slow waves at the left occipital region at 3 years and 6 months.
Patient 4 is a 2-year-old girl, who was the first child born to healthy nonconsanguineous parents with no anomalies. She experienced epileptic spasms at 6 months of age. EEG showed hypsarrhythmia (Supplementary Material, Fig. S1G ) and brain MRI was unremarkable (Supplementary Material, Fig. S2G and H). She was treated with ACTH, which was effective, but the epileptic spasms recurred immediately after stopping this treatment. At 9 months of age, she experienced focal seizures. Loss of consciousness, eye deviations to the right or the left and ipsilateral hemiconvulsions lasting for a minute were observed weekly. The seizures became intractable despite the administration of various anti-epileptic drugs including clonazepam, zonisamide, topiramate, levetiracetam, carbamazepine, perampanel, pyridoxal phosphate and repeated ACTH. Valproate was partially effective for the epileptic spasms and focal seizures. Vigabatrin was effective for the epileptic spasms, but single spasms remained. A ketogenic diet was begun. The patient presented with severe developmental delay. After the administration of vigabatrin at 20 months of age, partial rolling over and eye contact were acquired.
Patient 5 is a 5-year-old female, who was the first child born to non-consanguineous Japanese parents. Fetal ultrasonography showed severe hydrops fetalis with ascites and right hydronephrosis. She was delivered at 37 weeks of gestation. Her birth weight was 3098 g (þ1.5 SD), length 39 cm (À3.4 SD) and occipitofrontal circumference (OFC) 32.4 cm (À0.3 SD) . Hydrops, congenital ascites and right hydronephrosis were noted. She showed respiratory distress at the neonate stage and failed to thrive because of feeding difficulties in infancy. She was mechanically ventilated and tube-fed for a considerable time. She manifested craniofacial dysmorphism including brachycephaly with wide fontanels, hypertelorism, short nose, cleft palate and micrognathia. She also showed arthrogryposis (congenital multiple joint contractures) with bilateral talipes equinovalgus. Radiological examination showed severe slenderness of tubular bones (gracile bones) with bowing of radii and fracture of the left femur. The ribs were also slender with a small thorax. Cranial CT demonstrated ventriculomegaly and partial premature fusion of both coronal sutures, with delayed calvarial ossification. Fractures of the right radius and right femur occurred in the neonatal period. Urological assessment revealed hypoplasia of the left kidney with a severe vesicoureteral reflux. The clinical phenotype suggested a diagnosis of osteocraniostenosis, but molecular analysis for FAM111A was negative.
She underwent tracheostomy at 1 month of age, vesicocutaneostomy for vesicoureteral reflux at 1 year, gastrostomy at 3 years of age and repair for cleft palate at 6 years of age. Mental development and physical growth were severely delayed. At 5 years, she could not roll over, sit alone or speak meaningful words. Height was 87 cm (À4.4 SD), body weight 10.2 kg (À2.9 SD) and OFC 53 cm (þ1.9 SD). Cranial CT showed hydrocephalus and frontal plagiocephaly.
Patient 6 is a 7-year-old boy, who was the fourth child born to non-consanguineous healthy parents. He has two elder brothers and a sister. They are healthy with no seizure episodes. He was born by cesarean section at 37 weeks of gestation. Birth weight was 2815 g (À1.7 SD) and length 34 cm (À6.4 SD). Pedal edema was evident at birth. He obtained head control at 4 months of age, but sitting at 10 months, showing developmental delay. He could walk a couple of steps unaided at 4.5 years and speak two-and three-word sentences at 4.5 years. His DQ was 50 at the age of 4.5 years. He developed generalized seizures with fever at 5, 15 and 20 months. EEG showed abnormal background activity without epileptic discharge at 12 months and 4 years. His seizures were tractable and responded to lamotrigine, but abnormal background activity remained on EEG. Brain MRI showed periventricular white matter changes with asymmetric enlargement of the lateral ventricles (ventriculomegaly). He showed failure to thrive, short stature and microcephaly. At 4.5 years, his height was 85.0 cm (À5 SD), weight 10.0 kg (À4 SD) and head circumference 45.0 cm (À3.5 SD). In addition, he was clinically characterized by craniofacial and limb dysmorphic features including trigonocephaly, cleft palate, micrognathia, retrognathia, ptosis, arthrogryposis and brachydactyly.
WES analysis
WES was performed in all index patients and the parents of patients 1 and 5. DNA samples were captured by SureSelect XT Human All Exon V5 or V6 (Agilent Technologies) and sequenced on the Illumina HiSeq2500 with 101-bp paired-end reads (Illumina). Exome data processing, variant calling and annotation were performed as described previously (25, 26) . Average read depth of protein-coding regions ranged from 63Â to 141Â, and at least 92.9% of target bases were sequenced by ! 10 reads for each patient. Variants that fulfilled the following criteria were considered for further analysis: (1) variants with minor allele frequency < 0.1% in the Exome Sequencing Project (ESP6500), ExAC and our in-house Japanese exome database of 575 exomes; (2) possible pathogenicity based on mutation type (non-sense, missense, frameshift or splice site) with computational prediction of a deleterious protein function effect by SIFT, Polyphen-2, CADD and MutationTaster; and (3) de novo variants determined by subtracting variants found in either parent. Subsequently, PPP3CA variants were searched in our database of 1456 exomes of epilepsy patients as well as 1500 patients with various types of ID/MCA (KDM1A variants were also initially screened in 1456 exomes of epilepsy patients). All PPP3CA variants from each family were validated by Sanger sequencing regarding de novo occurrence.
PPP3CA expression analysis
In patient 4, total RNA was extracted from Epstein-Barr virustransformed lymphoblastoid cells using RNeasy Plus Mini kit (Qiagen). cDNA was synthesized from 1 lg of total RNA and random hexamers using PrimeScript 1 st strand cDNA synthesis kit (Takara). PPP3CA transcripts in a human multiple tissue cDNA panel (Clontech) were examined by PCR with primers at the exon 11-12 boundary (rt-F 11/12) and exon 14 (rt-R 14). Primer sequences are available on request. PCR included 35 cycles for qualitative splicing variant analysis, followed by electrophoresis in 2.5% agarose gels. Transcriptional variants 1 (NM_000944.4) and 2 (NM_001130691.1) were carefully examined by electrophoresis. For possible heteroduplex formation by different transcripts, a mismatch cleavage assay was performed using T7 endonuclease I (T7E1) to cleave heteroduplex DNA, in accordance with the manufacturer's instructions (New England Biolabs) (Supplementary Material, Fig. S5D ).
Calculation of free energy change due to mutation FoldX version 4.0 (9) was used to predict free energy change after mutation of the crystal structure of human calcineurin heterodimer (PDB code, 1AUI). RepairPDB, BuildModel and Stability commands implemented in FoldX software were used.
Yeast strains, media and growth conditions
For vegetative cell growth, rich media (YEA) or minimal media (EMM) were used with the addition of supplements as needed.
Strains transformed with pREP1-expression plasmid (LEU1 þ ) were grown in EMM-leu agar plates to maintain plasmids. For serial growth dilution assays, cells were cultured at 32 C to a cell density of OD 600 $0.5 and collected by centrifugation. Cell density was adjusted to OD 600 0.5 and 1.0 for YEA and EMM agar plates, respectively. Ten-fold serial dilutions were spotted. Cells were grown for 3 and 5 days at 32 C in YEA and EMM agar plates, respectively. For Ca 2þ sensitivity, CaCl 2 was added to YEA and EMM agar plates at a final concentration of 100 or 200 mM, respectively. FK506 (Tokyo Chemical Industry) and sodium valproate (Wako) were added to YEA agar plates at a final concentration of 0.5 lg/ml or 6 mM, respectively. Two independent experiments were performed for all serial growth dilution assays.
Plasmids
The S. pombe expression plasmid, pREP1, which has a thiaminerepressible nmt1 promoter, was used to overexpress ppb1 (27) . Full-length ppb1 cDNA (þ1 to þ1665) was obtained by reverse transcription (RT)-PCR and ligated into NdeI and BamHI restriction sites of pREP1. Site-directed mutagenesis using a KOD-PlusMutagenesis kit (Toyobo) was used to generate mutant ppb1 (p.His121Arg, p.Asn179Ile, p.Asp263Glu, p.Phe499Leu and p.Ala502Thr), in accordance with the manufacturer's instructions, except using PrimeSTAR V R HS DNA Polymerase (Takara).
Yeast strain construction
Strains expressing epitope-tagged proteins (Ppb1-HA and Prz1-GFP) under control of native promoters were constructed by a PCR-based method, as described previously (28) . For constructing ppb1 mutant alleles (Ppb1-HAHis121Arg, Ppb1-HAAsn179Ile, Ppb1-HAAsp263Glu, Ppb1-HAPhe499Leu and Ppb1-HAAla502Thr), the wild-type strain was transformed with a mutated ppb1 DNA fragment fused to HA and a nourseothricin resistance cassette (29) . ppb1 mutations in the correct chromosomal locations were confirmed by Sanger sequencing.
Cell extract preparation and western blot analysis
Ten milliliter cultures at a cell density of OD 600 0.5 were used to prepare whole-cell extracts. Wild-type and mutant strains were exponentially grown in YEA medium and treated with 100 or 200 mM CaCl 2 for 30 min. In some cases, cells were pretreated with FK506 at a final concentration of 0.5 lg/ml. Whole-cell extracts were prepared using the glass bead method combined with trichloroacetic acid precipitation. For Prz1 mobility shift, whole-cell extracts were resolved on 4%-12% NuPAGE Bis-Tris Protein Gels (Invitrogen) in 1Â NuPAGE SDS running buffer at a constant voltage of 200 V for 50 min, followed by western blotting. Anti-GFP (sc-9996; Santa Cruz Biotechnology), anti-HA (ab9110; Abcam) and anti-Cdc2 (sc-53217) were used for probing Prz1-GFP, Ppb1-HA and Cdc2, respectively.
Microscopy experiment
Live-cell imaging was performed on an FV1000-D confocal laser scanning microscope (Olympus) with a 60Â 1.35 numerical aperture oil lens. Exponentially growing cells (OD 600 $0.5) were treated with 200 mM CaCl 2 for 30 min. Two independent experiments were performed in each strain with or without 200 mM CaCl 2 .
RNA extraction and expression analysis for yeast
Total RNA was isolated from exponentially growing cultures using the Epicentre MasterPure Yeast RNA purification kit (Epicentre). cDNA was synthesized with 1 lg of total RNA and oligo dT primer using PrimeScript 1st strand cDNA synthesis kit (Takara). To quantify pmc1 and ncs1 expression, real-time quantitative PCR was performed. Rotor-Gene SYBR Green kit was used for real-time quantification of cDNA, with amplification monitored on the Rotor-Gene cycler system (Qiagen). Target gene expression was compared with that of an endogenous
